{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:05:14Z","timestamp":1789499114647,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Subcutaneous infliximab (SC-IFX) represents a significant advance for patients with inflammatory bowel disease (IBD) due to the possibility of home self-administration. However, at this time, there are no clear recommendations for implementing model-informed precision dosing (MIPD) in accordance with real-world clinical knowledge. Objective: The aim of the present study is to develop a population pharmacokinetic (PopPK) model for SC-IFX. Methods: A multicenter retrospective observational study was performed in adult patients (both na\u00efve patients and those switched from intravenous administration) diagnosed with IBD. PopPK analysis was performed using NONMEM with a nonlinear mixed-effects model approach. A stepwise covariate modeling approach was implemented to identify anthropometric and clinical factors influencing SC-IFX disposition. The bootstrap method was used for internal model validation. Results: A total of 250 serum concentration samples of IFX, corresponding to 45 patients, were analyzed. A one-compartment model with first-order absorption adequately described the data. The final model included total body weight and suspected immunogenicity as covariates of clearance (CL). Suspected immunogenicity was associated with a 70.0% increase in clearance, while each kg deviation from the median weight (73 kg) modified clearance by 0.888%\/kg. Conclusions: A PopPK model for SC-IFX was successfully developed and validated using European real-world data. This exploratory model establishes a foundation for future MIPD applications, offering a structured approach to initiate or transition patients to SC-IFX therapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091162","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:23:53Z","timestamp":1789496633000},"page":"1162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Subcutaneous Infliximab: A Real-World Study of Na\u00efve and Switch Patients"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1596-6275","authenticated-orcid":false,"given":"Blanca","family":"Vicente","sequence":"first","affiliation":[{"name":"Pharmacy Service, University Hospital of Salamanca, 37007 Salamanca, Spain"},{"name":"Area of Pharmacy and Pharmaceutical Technology, Pharmaceutical Sciences Department, Universidad de Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-4558","authenticated-orcid":false,"given":"Hinojal","family":"Zazo","sequence":"additional","affiliation":[{"name":"Area of Pharmacy and Pharmaceutical Technology, Pharmaceutical Sciences Department, Universidad de Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"software","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3686","authenticated-orcid":false,"given":"Jos\u00e9 Germ\u00e1n","family":"S\u00e1nchez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, University Hospital of Salamanca, 37007 Salamanca, Spain"},{"name":"Area of Pharmacy and Pharmaceutical Technology, Pharmaceutical Sciences Department, Universidad de Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1091-2758","authenticated-orcid":false,"given":"Natalia","family":"Revilla","sequence":"additional","affiliation":[{"name":"Pharmaceutical Pharmacy Service, University Hospital of Burgos, 09006 Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-4784","authenticated-orcid":false,"given":"Paulo","family":"Teixeira-da-Silva","sequence":"additional","affiliation":[{"name":"Area of Pharmacy and Pharmaceutical Technology, Pharmaceutical Sciences Department, Universidad de Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Dignass","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_2","unstructured":"(2025, June 21). Remicade|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade."},{"key":"ref_3","unstructured":"(2026, February 24). Remsima|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: The REMSWITCH Study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","first-page":"522","article-title":"Therapeutic Drug Monitoring in Inflammatory Bowel Diseases. Position Statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis","volume":"47","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic Drug Monitoring with Biologic Agents in Immune Mediated Inflammatory Diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_8","first-page":"225","article-title":"Los Niveles S\u00e9ricos de Infliximab y Adalimumab Est\u00e1n Asociados Con Remisi\u00f3n Profunda En La Enfermedad Inflamatoria Intestinal","volume":"45","year":"2021","journal-title":"Farm. Hosp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"jjae127","DOI":"10.1093\/ecco-jcc\/jjae127","article-title":"Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry","volume":"19","author":"Iborra","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/j.cgh.2023.01.004","article-title":"Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study","volume":"21","author":"Wang","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105369","DOI":"10.1016\/j.ejps.2020.105369","article-title":"Biomarkers of Disease Activity and Other Factors as Predictors of Adalimumab Pharmacokinetics in Inflammatory Bowel Disease","volume":"150","author":"Rebollo","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/apt.16609","article-title":"Population Pharmacokinetics of Subcutaneous Infliximab CT-P13 in Crohn\u2019s Disease and Ulcerative Colitis","volume":"54","author":"Hanzel","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/psp4.12838","article-title":"Efficient and Relevant Stepwise Covariate Model Building for Pharmacometrics","volume":"11","author":"Svensson","year":"2022","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated Covariate Model Building Within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1382-6689(96)00055-5","article-title":"Population Approaches\/Sparse Data Analysis for Human Variability in Kinetics and Dynamics","volume":"2","author":"Aarons","year":"1996","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"jjaf151","DOI":"10.1093\/ecco-jcc\/jjaf151","article-title":"Optimizing the Switch from Escalated Intravenous to Subcutaneous Infliximab: A Population Pharmacokinetics\u2013Pharmacodynamics Study","volume":"19","author":"Wang","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14309\/ajg.0000000000003466","article-title":"A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases","volume":"121","author":"Hoffert","year":"2026","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5009\/gnl240503","article-title":"Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study","volume":"19","author":"Song","year":"2025","journal-title":"Gut Liver"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"D\u00e9maris, A., Widigson, E.S.K., Ilvemark, J.F.K.F., Steenholdt, C., Seidelin, J.B., Huisinga, W., Michelet, R., Aulin, L.B.S., and Kloft, C. (2022). Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102095"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00296-014-3032-0","article-title":"Practical Application of Acid Dissociation in Monitoring Patients Treated with Adalimumab","volume":"34","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0004563218782286","article-title":"Therapeutic Drug Monitoring of Tumour Necrosis Factor Inhibitors in the Management of Chronic Inflammatory Diseases","volume":"56","author":"Rebollo","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0004563215604866","article-title":"Serum Trough Infliximab and Anti-Infliximab Antibodies in a Cohort of Gastroenterology and Rheumatology Patients\u2019 Infliximab Therapeutic Drug Monitoring","volume":"53","author":"Barlow","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Little, R.D., Ward, M.G., Wright, E., Jois, A.J., Boussioutas, A., Hold, G.L., Gibson, P.R., and Sparrow, M.P. (2022). Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206173"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher Serum Infliximab Concentrations Following Subcutaneous Dosing Are Associated with Deep Remission in Patients with Inflammatory Bowel Disease","volume":"18","author":"Roblin","year":"2024","journal-title":"J. Crohns Colitis"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:28:40Z","timestamp":1789496920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091162"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091162","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}